Enveric director granted 18,518 restricted shares

PASQUALONE FRANK reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

PASQUALONE FRANK reported acquisition or exercise transactions in this Form 4 filing.

Enveric Biosciences director Frank Pasqualone received a grant of restricted stock. He was awarded 18,518 shares of common stock at no cash cost under the company’s 2020 Long-Term Incentive Plan. These shares will vest over time according to the plan and his award agreement.

After this equity grant, Pasqualone directly holds 26,423 shares of Enveric Biosciences common stock. This filing reflects a compensation-related stock award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 18,518 shares

Grant/Award 1 txn

Insider PASQUALONE FRANK

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	18,518	$0.00	$0.00

Holdings After Transaction: Common Stock — 26,423 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

Key Figures

Restricted stock grant: 18,518 shares Grant price per share: $0.00 per share Shares held after grant: 26,423 shares +1 more

4 metrics

Restricted stock grant 18,518 shares Common Stock granted to director on 2026-06-01

Grant price per share $0.00 per share Restricted stock award under 2020 Long-Term Incentive Plan

Shares held after grant 26,423 shares Total common stock directly owned after transaction

Transaction code A (Grant, award, or other acquisition) Indicates equity award rather than market purchase

Key Terms

restricted stock, 2020 Long-Term Incentive Plan, Form 4, Grant, award, or other acquisition

4 terms

restricted stock financial

"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2020 Long-Term Incentive Plan financial

"pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan")"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Enveric Biosciences (ENVB) report for Frank Pasqualone?

Enveric Biosciences reported that director Frank Pasqualone received 18,518 shares of restricted common stock. The grant was made at no cash cost as part of his equity compensation under the company’s 2020 Long-Term Incentive Plan, increasing his direct holdings.

How many Enveric Biosciences (ENVB) shares does Frank Pasqualone hold after this Form 4?

Following the restricted stock grant, Frank Pasqualone holds 26,423 shares of Enveric Biosciences common stock directly. This reflects his updated ownership position after receiving 18,518 restricted shares awarded as compensation under the company’s long-term incentive plan.

Was the Enveric Biosciences (ENVB) Form 4 transaction an open-market buy or sell?

The Form 4 transaction was not an open-market buy or sell. It reports a grant of 18,518 restricted shares to director Frank Pasqualone at a price of $0.00 per share as equity compensation, subject to vesting terms under the long-term incentive plan.

Under which plan did Enveric Biosciences (ENVB) grant restricted stock to Frank Pasqualone?

The restricted stock was granted under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. The 18,518 shares are subject to vesting based on the plan’s provisions and the specific terms in Pasqualone’s restricted stock award agreement.

What does restricted stock mean in the Enveric Biosciences (ENVB) Form 4 filing?

Restricted stock refers to shares granted as compensation that vest over time or upon conditions. In this case, 18,518 Enveric Biosciences shares granted to director Frank Pasqualone will vest under the 2020 Long-Term Incentive Plan and his award agreement terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PASQUALONE FRANK

(Last) (First) (Middle)

245 FIRST STREET, RIVERVIEW II

18TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enveric Biosciences, Inc. [ ENVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		18,518(1)	A	$0	26,423	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

	/s/ Frank Pasqualone	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)